On the HCPLive Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.
October 26th 2024
In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.
Breakthroughs in Atopic Eczema Treatment and Prevention Highlighted in Year-End Reviews
December 23rd 2016The second of a two-part, year-end review of advances against eczema/dermatitis (AD) focused on treatment and prevention, noting there was little evidence showing "relative efficacy" of common systemic treatments.
Genotyping Promises Precision Treatment of Atopic Eczema
December 19th 2016The first study to associate genetic variances linked to skin barrier deficiencies and immune response in atopic eczema/dermatitis with the responses to treatment over several years has moved the field closer to individualizing precision therapies for the condition.
One Treatment Option for Pediatric Eczema Might Already Be in Your Bathroom Cabinet
Skin conditions can cause physical, emotional, and financial duress. And, since atopic dermatitis in infants is often linked with asthma, allergies, hay fever, sleep problems, and weight issues, the total cost of eczema treatment could scale $3.8 billion annually.
Probiotics May Prevent Atopic Dermatitis if Microbiome Cooperates
December 13th 2016Previous research showed probiotics given to pregnant women during certain stages of pregnancy and post delivery reduced the likelihood of atopic dermatitis in their children. Recently published reports; however, may not agree.
Atopic Dermatitis Patients Risk Contact Dermatitis from Topical Treatments
December 12th 2016Children with atopic dermatitis (AD) were reported to have a greater risk for developing contact dermatitis from some common ingredients of topical products than those with a history of contact dermatitis but no AD, in a recent comparison of patch testing responses in both groups.
EU Regulators Accept Dupilumab for Review
Regeneron and Sanofi’s highly-anticipated atopic dermatitis drug dupilumab, trade name Dupixent, has been accepted by the European Medicines Agency (EMA) for review. The drug has performed well in trials and is considered an impending blockbuster.
Researchers Examine the Role of Biofilms in Atopic Dermatitis and Psoriasis
“While the concept of biofilms in atopic dermatitis is relatively new, antimicrobial and biofilm dispersing agents have been included in the treatment regimen for atopic dermatitis for decades," according to the study authors.
Which Emollient Makes Atopic Dermatitis Worse?
November 21st 2016Multiple measurements of skin integrity and function were applied to distinguish between the effects of topical emollient products in a recent study. Two popular products in the UK were determined to transiently improve the skin barrier that is thought to be defective in atopic dermatitis (AD), and another product was confirmed to be damaging.
Testing Ustekinumab for Severe Atopic Dermatitis
October 31st 2016Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.
Reviewing Potential Atopic Dermatitis Treatments and Pathogeneses
A recent review of current research on atopic dermatitis (AD) treatments found that a clearer understanding of the pathogenesis of the phenotypes involved in the disease will lead to advances in new therapies.
New Trials Bolster Dupilumab's “First Line Treatment†Potential for Atopic Dermatitis
Eric Simpson, MD, the lead author on the study, spoke to MD Magazine about the results, which showed great improvement with few side effects for those with moderate or severe atopic dermatitis.
Too Many Ways to Measure an Itch, Derm Study Finds
October 12th 2016Dermatitis researchers use far too many instruments in measuring symptoms of skin ailments, a study found. Symptoms of atopic ezcema/dermatitis (AD) were found in a systematic review of randomized controlled trials (RCTs) to be most often characterized from composite measures rather than stand-alone symptom severity rating instruments, and thirty different instruments were found to have been used across 378 trials.
Early Subcutaneous Allergen Immunotherapy Works for Certain Patients
October 12th 2016Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.
Atopic Dermatitis: Immunotherapy Can Be Effective
October 10th 2016Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.